Back to Search Start Over

Cost-Effectiveness of Whole-Genome vs Whole-Exome Sequencing Among Children With Suspected Genetic Disorders

Authors :
Nurchis, Mario Cesare
Radio, Francesca Clementina
Salmasi, Luca
Heidar Alizadeh, Aurora
Raspolini, Gian Marco
Altamura, Gerardo Andrea
Tartaglia, Marco
Dallapiccola, Bruno
Pizzo, Elena
Gianino, Maria Michela
Damiani, Gianfranco
Nurchis, Mario Cesare (ORCID:0000-0002-9345-4292)
Salmasi, Luca (ORCID:0000-0001-6674-9215)
Altamura, Gerardo
Damiani, Gianfranco (ORCID:0000-0003-3028-6188)
Nurchis, Mario Cesare
Radio, Francesca Clementina
Salmasi, Luca
Heidar Alizadeh, Aurora
Raspolini, Gian Marco
Altamura, Gerardo Andrea
Tartaglia, Marco
Dallapiccola, Bruno
Pizzo, Elena
Gianino, Maria Michela
Damiani, Gianfranco
Nurchis, Mario Cesare (ORCID:0000-0002-9345-4292)
Salmasi, Luca (ORCID:0000-0001-6674-9215)
Altamura, Gerardo
Damiani, Gianfranco (ORCID:0000-0003-3028-6188)
Publication Year :
2024

Abstract

Importance The diagnosis of rare diseases and other genetic conditions can be daunting due to vague or poorly defined clinical features that are not recognized even by experienced clinicians. Next-generation sequencing technologies, such as whole-genome sequencing (WGS) and whole-exome sequencing (WES), have greatly enhanced the diagnosis of genetic diseases by expanding the ability to sequence a large part of the genome, rendering a cost-effectiveness comparison between them necessary. Objective To assess the cost-effectiveness of WGS compared with WES and conventional testing in children with suspected genetic disorders. Design, Setting, and Participants In this economic evaluation, a bayesian Markov model was implemented from January 1 to June 30, 2023. The model was developed using data from a cohort of 870 pediatric patients with suspected genetic disorders who were enrolled and underwent testing in the Ospedale Pediatrico Bambino Gesu, Rome, Italy, from January 1, 2015, to December 31, 2022. The robustness of the model was assessed through probabilistic sensitivity analysis and value of information analysis. Main Outcomes and Measures Overall costs, number of definitive diagnoses, and incremental cost-effectiveness ratios per diagnosis were measured. The cost-effectiveness analyses involved 4 comparisons: first-tier WGS with standard of care; first-tier WGS with first-tier WES; first-tier WGS with second-tier WES; and first-tier WGS with second-tier WGS. Results The ages of the 870 participants ranged from 0 to 18 years (539 [62%] girls). The results of the analysis suggested that adopting WGS as a first-tier strategy would be cost-effective compared with all other explored options. For all threshold levels above euro29 800 (US $32 408) per diagnosis that were tested up to euro50 000 (US $54 375) per diagnosis, first-line WGS vs second-line WES strategy (ie, 54.6%) had the highest probability of being cost-effective, followed by first-line vs second-line WGS (

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1439664242
Document Type :
Electronic Resource